Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.85 |
| ▸ | ABL1 | P00519 | 2/20 | 0.75 |
| ▸ | BCR | P11274 | 1/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.71 |
| ▸ | FYN | P06241 | 1/20 | 0.71 |
| ▸ | LYN | P07948 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218806 | 0.92 | SRC (0.85) | SRCEGFRABL1BCRERBB2 | |
| SCHEMBL29385888 | 0.92 | SRC (1.00) | SRCEGFRABL1BCRERBB2 | |
| SCHEMBL4961809 | 0.92 | SRC (1.00) | SRCEGFRABL1BCRERBB2 | |
| SCHEMBL4963092 | 0.91 | SRC (1.00) | SRCEGFRABL1BCRERBB2 | |
| SCHEMBL4963122 | 0.88 | SRC (1.00) | SRCEGFRABL1BCRERBB2 | |
| SCHEMBL6184535 | 0.84 | SRC (0.80) | SRCEGFRABL1BCRERBB2 | |
| SCHEMBL6184821 | 0.84 | SRC (0.87) | SRCEGFRABL1BCRERBB2 | |
| SCHEMBL6184034 | 0.84 | SRC (0.92) | SRCEGFRABL1BCRERBB2 | |
| SCHEMBL4962546 | 0.84 | SRC (0.81) | SRCEGFRABL1BCR | |
| SCHEMBL4123796 | 0.83 | SRC (1.00) | SRCEGFRABL1BCRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802581-B1 | 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH CORP (US) | 2008-04-02 | — | — | EP | claimed |
| EP-1802581-A1 | 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060116375-A1 | 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury | WYETH (US) | 2006-06-01 | — | — | US | claimed |
| WO-2006047262-A1 | 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2006-05-04 | — | — | WO | claimed |
| EP-1802581-B1 | 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH CORP (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1802581-A1 | 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060116375-A1 | 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury | WYETH (US) | 2006-06-01 | — | — | US | disclosed |
| WO-2006047262-A1 | 4 [(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-7-ETHYNYL-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116375-A1 | 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury | TNNI3, SUCNR1, EDNRA | SRC 3051/4885EGFR 2535/4885ABL1 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.